|
[1] JEMAL A, SIEGEL R, XU J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60 (5) :277-300.
|
|
[2]LLOVET JM, BURROUGHS A, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2003, 362 (9399) :1907-1917.
|
|
[3]PARKIN DM, BRAY F, FERLAY J, et al.Globle cancer statistics, 2002[J].CA Cancer J Clin, 2005, 55 (2) :74-108.
|
|
[4]TAIEB J, BARBARE JC, ROUGIER P.Medical treatments for hepatocellular carcinoma (HCC) :what’s next?[J].Ann Oncol, 2006, 17 (Suppl 10) :x308-x314.
|
|
[5]ROUGIER P, MITRY E, BARBARE JC, et al.Hepatocellular carcinoma (HCC) :an update[J].Semin Oncol, 2007, 34 (2) :s12-s20.
|
|
[6]HSU C, SHEN YC, CHENG CC, et al.Geographic difference in survival outcome for advanced hepatocellular carcinoma:implications on future clinical trial design[J].Contemp Clin Trials, 2010, 31 (1) :55-61.
|
|
[7]PALMER DH, HUSSAIN SA, JOHNSON PJ.Systemic therapies for hepatocellular carcinoma[J].Expert Opin Invest Drugs, 2004, 13 (12) :1555-1568.
|
|
[8]MINSIG C, JEFFREY J, PHILIP A.Combining sorafenib with chemoembolization for hepatocellular cancer[J].Commun Oncol, 2011, 8 (5) :216-219.
|
|
[9] WILHELM SM, CARTER C, TANG L, et al.BAY 43-9006 exhibits broad spectrumoral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res, 2004, 64 (19) :7099-7109.
|
|
[10] LLOVET JM, RICCI C, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.
|
|
[11]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomized, double-mind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.
|
|
[12] MAZZAFERRO V, REGALIA E, DOCI K, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].N Engl J Med, 1996, 334 (1) :693-699.
|
|
[13]TANG ZY.The significance and means of research on hepatocellular carcinoma’s recurrence and metastasis[J].Chin J Gen Surg, 2006, 21 (11) :761. (in Chinese) 汤钊猷.开展肝癌转移复发研究的意义和途径[J].中华普通外科杂志, 2006, 21 (11) :761.
|
|
[14] LIU LG, MIU RY, LU X, et al.A survival analysis of patients with early-stage hepatocellular carcinoma fulfilling Milan criteria and undergoing hepatectomy[J].Natl Med J China, 2010, 90 (46) :3251-3254. (in Chinese) 刘立国, 缪若羽, 卢欣, 等.符合米兰标准的的早期肝癌患者肝切除术后生存分析[J].中华医学杂志, 2010, 90 (46) :3251-3254.
|
|
[15]LIANG TB, GENG L.Thinking about the current situation and relapse prevention of liver transplantation[J].Natl Med J China, 2011, 91 (22) :1516-1518. (in Chinese) 梁廷波, 耿磊.对肝癌肝移植现状和复发防治的思考[J].中华医学杂志, 2011, 91 (22) :1516-1518.
|
|
[16]SAAB S, MCTIGUE M, FINN RS, et al.Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients:feasibility and efficacy[J].Exp Clin Transplant, 2010, 8 (4) :307-313.
|
|
[17]YOON DH, RYOO BY, RYU MH, et al.Sorafenib for recurrent hepatocellular carcinoma after liver transplantation[J].Jpn J Clin Oncol, 2010, 40 (8) :768-773.
|
|
[18]YANG ZL, ZOU WW.Prevention of tumor recurrence with Sorafenib after liver transplantation in rat with liver cancer[J/CD].Chin J Clinicians:Electronic Edition, 2011, 5 (2) :335-342. (in Chinese) 杨振林, 邹伟伟.索拉非尼防治大鼠肝癌肝移植术后肿瘤转移复发的研究[J/CD].中华临床医师杂志:电子版, 2011, 5 (2) :335-342.
|
|
[19]HUANG L, ZHU JY, SU GM, et al.Postoperative use of Sorafenib in liver transplantation patients of hepatocellular carcinoma beyond Milan criteria[J].Chin J Gen Surg, 2011, 26 (11) :936-939. (in Chinese) 黄磊, 朱继业, 粟光明, 等.索拉非尼预防超米兰标准肝癌患者肝移植术后复发[J].中华普通外科杂志, 2011, 26 (11) :936-939.
|
|
[20]HU AB, HE XS, TAI Q, et al.Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation[J].Natl Med J China, 2012, 92 (18) :1264-1267. (in Chinese) 胡安斌, 何晓顺, 邰强, 等.索拉非尼在预防和治疗肝癌肝移植术后肿瘤复发中的疗效评价[J].中华医学杂志, 2012, 92 (18) :1264-1267.
|
|
[21]LI Q, HAN P.OT assessment after radiofrequency ablation of hepatocellular carcinoma:From morphology to function[J].Chin J Med Imaging Technol, 2013, 29 (2) :314-317. (in Chinese) 李骞, 韩萍.肝癌射频消融术后疗效的CT形态学和功能学评价[J].中国医学影像技术, 2013, 29 (2) :314-317.
|
|
[22]LIU X, LYU WF.Imaging evaluation on the curative effect of radiofrequency ablation for primary hepatic carcinoma[J].Chin J Interv Imaging Ther, 2012, 9 (2) :136-138. (in Chinese) 刘昕, 吕维富.影像学评价射频消融治疗肝癌的疗效[J].中国介入影像与治疗学, 2012, 9 (2) :136-138.
|
|
[23] LIVRAGHI T, GOLDBERG SN, LAZZARONI S, et al.Hepatocellular carcinoma:radio-frequency ablation of medium and large lesions[J].Radiology, 2000, 214 (3) :761-768.
|
|
[24] DODD GD, SOULEN MC, KANE RA, et al.Minimally invasive treatment of malignant hepatic tumors:at the threshold of a major breakthrough[J].Radiographics, 2000, 20 (1) :9-27.
|
|
[25]European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol, 2012, 56 (4) :908-943.
|
|
[26]KNZLI BM, ABITABILE P, MAURER CA.Radiofrequency ablation of liver tumors:Actual limitations and potential solutions in the future[J].World J Hepatol, 2011, 3 (1) :8-14.
|
|
[27]KIM JW, KIM JH, WON HJ, et al.Hepatocellular carcinomas2-3 cm in diameter:transarterial chemoembolization plus radiofrequency ablation vs.radiofrequency ablation alone[J].Eur J Radiol, 2012, 81 (3) :e189-e193.
|
|
[28]MERTENS JC, MARTIN IV, SCHMITT J, et al.Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals[J].Eur J Radiol, 2012, 81 (7) :1601-1606.
|
|
[29]XU M, XIE XH, XIE XY, et al.Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy:an experiment in vivo[J].Acta Radiol, 2013, 54 (2) :199-204.
|
|
[30]SUN JJ, ZHAO HJ, LI W, et al.Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (10) :1093-1098. (in Chinese) 孙景娟, 赵恒军, 李薇, 等.射频消融联合索拉非尼治疗进展期肝细胞癌的临床观察[J].临床肝胆病杂志, 2011, 27 (10) :1093-1098.
|
|
[31] TANG Z, WU YL.Combining radiofrequency ablation (RFA) with Sorafenib therapy for liver tumor ablation efficacy:study on mice and patients[D].Zhejiang:Zhejiang University, 2012. (in Chinese) 唐喆, 吴育连.索拉非尼联合射频消融治疗肝癌的临床和实验研究[D].浙江:浙江大学, 2012.
|
|
[32]LO CM, NGAN H, TSO WK, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology, 2002, 35 (5) :1164-1174.
|
|
[33]LLOVET JM, REAL MI, MONTAAX, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet, 2002, 359 (9319) :1734-1739.
|
|
[34]LLOVET JM, BRUIX J.Systematic review of randomized trials for unresectable hehepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology, 2003, 37 (2) :429-442.
|
|
[35]FORNER A, TRINCHET JC.Transarterial therapies in HCC:does embolization increase survival?[J].J Hepatol, 2009, 51 (6) :981-983.
|
|
[36]SERGIO A, CRISTOFORI C, CARDIN R, et al.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) :the role of angiogenesis and invasiveness[J].Am J Gastroenterol, 2008, 103 (4) :914-921.
|
|
[37]MATHONNET M, DESCOTTES B, VALLEIX D, et al.Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma[J].World J Gastroenterol, 2006, 12 (23) :3782-3783.
|
|
[38]CHUNG Y, KIM B, CHEN C, et al.Study in Asia of the combination of transarterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma trial (START) :second interim safety and efficacy analysis[J].J Clin Oncol, 2010, 28 (Suppl15) :4026.
|
|
[39] QU XD, CHEN CS, WANG JH, et al.The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma[J].BMC Cancer, 2012, 12:263.
|
|
[40]BAI W, WANG YJ, ZHAO Y, et al.Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma:a propensity score matching study[J].J Dig Dis, 2013, 14 (4) :181-190.
|
|
[41]WANG HL, ZHONG JH, MA L, et al.The efficacy of transarterial chemoembolization plus Sorafenib for advanced hepatocellular carcinoma:a systematic review[J/CD].Chin J Clinicians:Electronic Edition, 2012, 6 (23) :7653-7658. (in Chinese) 王洪良, 钟鉴宏, 马良, 等.肝动脉化疗栓塞联合索拉非尼治疗中晚期肝细胞癌疗效的系统评价[J/CD].中华临床医师杂志:电子版, 2012, 6 (23) :7653-7658.
|
|
[42] ZHENG JP, SHAO GL, CHEN YT, et al.Clinical research of sorafenib plus TACE in hepatocellular carcinoma with multiple pulmonary metaststasis[C]∥1thZhejiang and Jiangxi province Cancer Research Papers assembly.2012:831-834. (in Chinese) 郑家平, 邵国良, 陈玉堂, 等.索拉非尼联合TACE治疗肝细胞肝癌多发肺转移的临床研究[C]∥首届浙赣两省肿瘤研究交流会论文汇编.2012:831-834.
|
DownLoad: